Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Avicanna ( (TSE:AVCN) ) has shared an update.
Avicanna has announced a new collaboration with Vectura Fertin Pharma to enhance research and medical affairs initiatives related to medical cannabis in Canada. This partnership aims to improve medical cannabis access and application by engaging with healthcare professionals, patients, and insurers, leveraging Avicanna’s medical cannabis platform to address challenges and support patient needs.
More about Avicanna
Avicanna is a commercial-stage international biopharmaceutical company specializing in the development and commercialization of cannabinoid-based products. Their offerings include a diverse range of medical cannabis formulations, a care platform for medical cannabis patients, a pharmaceutical pipeline targeting unmet medical needs, and active pharmaceutical ingredients. These products cater to global medical and pharmaceutical markets, with a strong presence in Canada and ongoing expansion into international markets.
YTD Price Performance: 4.55%
Average Trading Volume: 11,955
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $26.13M
See more insights into AVCN stock on TipRanks’ Stock Analysis page.